What were the results of the SURMOUNT cardiovascular outcomes trial of tirzepatide, and how should tirzepatide be incorporated into clinical practice for adults with type 2 diabetes and established or high cardiovascular risk?

SURMOUNT-CVOT Trial Results and Clinical Application

Tirzepatide demonstrated noninferiority but not superiority to dulaglutide for cardiovascular outcomes in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, with a 12.2% event rate versus 13.1% (HR 0.92; 95.3% CI 0.83-1.01; p=0.09 for superiority). 1

Key Trial Results

The SURPASS-CVOT trial (also referred to as SURMOUNT-CVOT) enrolled 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease, comparing tirzepatide (up to 15 mg weekly) versus dulaglutide (1.5 mg weekly). 1

Primary Endpoint (3-point MACE):

• Composite of cardiovascular death, myocardial infarction, or stroke occurred in 801 patients (12.2%) with tirzepatide versus 862 patients (13.1%) with dulaglutide 1
• Hazard ratio: 0.92 (95.3% CI: 0.83-1.01) 1
• Met noninferiority criteria (p=0.003) but did not achieve superiority (p=0.09) 1

Patient Population Characteristics:

• Mean age: 64.1 years 1
• 29% women 1
• Mean BMI: 32.6 kg/m² 1
• Mean HbA1c: 8.4% 1
• Mean diabetes duration: 14.7 years 1

Safety Profile:

• Similar overall adverse event rates between groups 1
• More gastrointestinal adverse events with tirzepatide 1

Clinical Practice Integration

When to Use Tirzepatide

First-Line Consideration (After Metformin):

For patients with type 2 diabetes and established cardiovascular disease requiring both glycemic control and weight loss, tirzepatide represents a reasonable alternative to GLP-1 receptor agonists with proven cardiovascular benefit. 1, 2

• Tirzepatide provides superior weight reduction compared to traditional GLP-1 agonists (mean weight loss 15-20.9% at higher doses) 2
• Demonstrated cardiovascular safety equivalent to dulaglutide, which has established cardiovascular benefit 1, 2

Preferred Patient Profiles:

• Type 2 diabetes with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related complications 3
• Established atherosclerotic cardiovascular disease requiring intensive weight management 1
• HbA1c >8% requiring substantial glycemic improvement 1
• Patients who have not achieved adequate weight loss with other GLP-1 agonists 2

Dosing Algorithm

Initiation and Titration:

• Start: 2.5 mg subcutaneously once weekly 2
• Titrate slowly every 4 weeks to reduce gastrointestinal side effects 2
• Target maintenance: 10-15 mg weekly for cardiovascular risk reduction 1
• Maximum dose tested in cardiovascular outcomes: 15 mg weekly 1

Dose Modifications:

• Up-titrate slowly to minimize nausea and vomiting 2
• If intolerable gastrointestinal symptoms occur, maintain current dose for additional 4 weeks before advancing 2
• Reduce meal size and avoid high-fat foods to improve tolerability 2

Contraindications and Cautions

Absolute Contraindications:

• Personal or family history of medullary thyroid cancer 2
• Multiple endocrine neoplasia type 2 (MEN2) 2
• History of serious hypersensitivity to tirzepatide 2
• Pregnancy or breastfeeding 2

Use with Caution:

• Severe renal impairment (eGFR <30 mL/min/1.73 m²): use not recommended for some GLP-1 agonists 2
• History of pancreatitis: discontinue if suspected and do not restart if confirmed 2
• Clinically meaningful gastroparesis: not recommended due to delayed gastric emptying 2
• Prior gastric or bariatric surgery: exercise caution 2
• Diabetic retinopathy: monitor closely, as rapid glycemic improvement may worsen retinopathy 2

Hypoglycemia Risk Management:

• Increased risk when combined with insulin, sulfonylureas, or glinides 2
• Consider reducing insulin dose by ~20% when initiating tirzepatide 2
• Wean or stop sulfonylurea/glinide if HbA1c well-controlled at baseline 2

Positioning Relative to Other Agents

Compared to GLP-1 Receptor Agonists:

Tirzepatide offers greater weight loss but equivalent (not superior) cardiovascular protection compared to dulaglutide. 1

• Liraglutide and semaglutide have demonstrated superiority for MACE reduction (HR 0.87 and 0.74, respectively) 2
• Tirzepatide showed noninferiority but not superiority (HR 0.92) 1
• For patients prioritizing weight loss over proven cardiovascular superiority, tirzepatide is preferred 2, 3
• For patients prioritizing maximal cardiovascular risk reduction, semaglutide or liraglutide remain preferred 2

Compared to SGLT-2 Inhibitors:

For comprehensive cardiovascular and renal protection, consider combining tirzepatide with an SGLT-2 inhibitor rather than choosing one over the other. 2

• SGLT-2 inhibitors reduce all-cause mortality, MACE, heart failure hospitalization, and chronic kidney disease progression 2
• Tirzepatide reduces albuminuria without adverse eGFR changes 4
• SGLT-2 inhibitors provide specific heart failure benefits not demonstrated with GLP-1 agonists 2
• Combination therapy addresses complementary mechanisms 2

Monitoring Requirements

Baseline Assessment:

• HbA1c, fasting glucose 1
• Lipid panel, blood pressure 3
• eGFR, urine albumin-to-creatinine ratio 4
• Thyroid function if family history of thyroid cancer 2
• Baseline weight and BMI 1

Ongoing Monitoring:

• HbA1c every 3 months until stable, then every 6 months 2
• Weight and blood pressure at each visit 3
• Annual urine albumin-to-creatinine ratio and eGFR 4
• Monitor for gastrointestinal symptoms, especially during titration 2
• Assess for signs/symptoms of pancreatitis 2
• If on insulin or sulfonylureas, monitor for hypoglycemia 2

Common Pitfalls to Avoid

Titration Errors:

• Advancing dose too rapidly leads to intolerable gastrointestinal side effects and discontinuation 2
• Maintain each dose for minimum 4 weeks before escalating 2

Inappropriate Patient Selection:

• Do not use tirzepatide as first-line monotherapy without metformin in most patients 2
• Avoid in patients with gastroparesis or severe gastrointestinal disease 2
• Screen for personal/family history of medullary thyroid cancer before initiating 2

Medication Interactions:

• Failure to reduce insulin or sulfonylurea doses increases hypoglycemia risk 2
• Delayed gastric emptying may affect absorption of oral medications; separate timing if needed 2

Discontinuation Before Surgery:

• Consider holding tirzepatide 3-7 days before elective surgery due to delayed gastric emptying and aspiration risk 2
• Similar precautions as with other GLP-1 agonists 2

Cost and Access Considerations

While not explicitly addressed in the cardiovascular outcomes trial, tirzepatide represents a newer, potentially more expensive option compared to established GLP-1 agonists with proven cardiovascular superiority. 1 The decision should weigh the substantial weight loss benefits against the lack of proven cardiovascular superiority and potential cost differences. 1, 2